Physician profile
Corazon Brittain
NPI 1629657929
$3,298.44
in general payments reported to CMS, 2019-2025
18 companies · $1,332 in 2025
The $1,332 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $311 · 2022: $571 · 2023: $459 · 2024: $625 · 2025: $1,332.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,717 · Travel and Lodging: $699.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,716.84 |
| Travel and Lodging | $699.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,034.19 | 2021-2025 | Watchman, Patientcare Link |
| Novartis Pharmaceuticals Corporation | $360.94 | 2021-2024 | |
| Shockwave Medical, INC | $346.84 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $214.99 | 2022-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $211.80 | 2021-2025 | Verquvo |
| Pfizer INC. | $203.79 | 2022-2023 | |
| Astrazeneca Pharmaceuticals Lp | $184.46 | 2022 | |
| Edwards Lifesciences Corporation | $159.13 | 2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Novo Nordisk INC | $140.08 | 2022-2025 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.77 | 2022-2023 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $111.93 | 2021-2023 | |
| Angiodynamics, INC. | $57.08 | 2023 | Alphavac |
| Amgen INC. | $46.39 | 2024-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $20.45 | 2025 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $19.01 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medicomp INC | $17.75 | 2023 | Telepatch Cardiac Monitor |
| Amarin Pharma, INC. | $15.84 | 2021 | |
| Celgene Corporation | $15.00 | 2025 | Reblozyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corazon Brittain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.